AbbVie Inc. (ABBV) earnings on July 31, 2026

Before the market opens Q2 2026

More AbbVie Inc. earnings

Prior outlook: No statistical edge

After reporting earnings, the stock swung widely, dropping as much as 5% before closing down about 2%. The market's reaction was negative.

ABBV price around the earnings

250.94

Change: -2.5%

2026-07-31, 20:00 UTC

Start of the measured window End of the measured window
245.00 249.58 254.15 258.73 257.46
Price series around the eventClosing price per minute from before the event to the end of the measured window.
July 31, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: No statistical edge

Thesis published
Results released

Context analyzed before publication

Analysts

Evidence

Analyst consensus
Buy
Consensus average (1-5)
1.74
Analysts covering the stock
28
Average price target
268.68
Lowest price target
200
Highest price target
328
Upside to price target
4.4%
Quarterly earnings growth
-46%
Revenue growth
12.4%
Forward EPS
16.3
Trailing EPS
1.98
Analyst moves in the last 60 days
10
  • Strong buy: 8
  • Buy: 16
  • Hold: 6
  • Sell: 0
  • Strong sell: 1
Strong buy
8
Buy
16
Hold
6
Sell
0
Strong sell
1
  • July 29, 2026 · Barclays: Maintains rating (Overweight → Overweight)
  • July 22, 2026 · Canaccord Genuity: Maintains rating (Buy → Buy)
  • July 15, 2026 · Citigroup: Maintains rating (Neutral → Neutral)
  • July 13, 2026 · UBS: Maintains rating (Neutral → Neutral)
  • July 13, 2026 · BMO Capital: Maintains rating (Outperform → Outperform)
  • July 10, 2026 · B of A Securities: Maintains rating (Buy → Buy)
  • July 10, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
  • July 10, 2026 · Wells Fargo: Maintains rating (Overweight → Overweight)
  • July 9, 2026 · Guggenheim: Maintains rating (Buy → Buy)
  • July 9, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)

News and sentiment

Evidence

Sentiment
Sentiment
Constructive
Mention volume
Low
Normalized volume
33%
News
Sources (6)

Technicals

Evidence

Price when the context was analyzed
257.5
Average true range (ATR)
2.5%
Distance to 52-week high
-2.2%
14-day change (14d)
+1.2%
30-day change (30d)
+2.4%
30-day relative strength
+3.1%
SPY change (30d)
-0.7%
Nearest support
256.75
Distance to nearest support
0.3%
Nearest resistance
258.2
Distance to nearest resistance
0.3%
Volume accumulation ratio (14d / 46d)
1.03
  • Mid: 256.75 (0.3% away, 0.12 ATR, 19 touches)
  • Minor: 254.51 (1.2% away, 0.47 ATR, 7 touches)
  • Mid: 253.21 (1.7% away, 0.68 ATR, 19 touches)
  • Mid: 258.2 (0.3% away, 0.11 ATR, 10 touches)
  • Mid: 260.19 (1.1% away, 0.43 ATR, 15 touches)
  • Minor: 261.57 (1.6% away, 0.64 ATR, 2 touches)

Trends

Evidence

Average earnings surprise
+1.9%
  • April 29, 2026: actual EPS 2.65 vs estimate 2.67 (surprise -0.8%)
  • February 4, 2026: actual EPS 2.71 vs estimate 2.65 (surprise +2.2%)
  • October 31, 2025: actual EPS 1.86 vs estimate 1.78 (surprise +4.2%)
  • July 31, 2025: actual EPS 2.97 vs estimate 2.91 (surprise +2.1%)

Expected move

Implied move
+0.0%
Source
Options chain

Reactions over its last 20 earnings

Median move
4%
75th percentile move
4.7%
90th percentile move
6.1%
Up / down moves
10 / 10
Average up move
+3.5%
Average down move
-4.1%

Monitoring and close

What AbbVie Inc. reported

Status
Finished
Actual EPS3.65
EPS estimate3.6
EPS surprise+1.4%
Revenue$16,990 million
Revenue estimate$16,765 million
Revenue surprise+1.3%

AbbVie beat Q2 forecasts as Skyrizi sales surged 24%, but slashed full-year guidance due to the pending Apogee acquisition. Shares fell.

Sources (21)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating -3.5% pre-market, a move in line with the stock's usual reaction (about 4%). The figures don't confirm the prior scenario: there was no prior directional scenario to check against.

How the stock reacted

Consolidated
-2.2%
Max move
-5.1%

No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.